Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Status:
Not yet recruiting
Trial end date:
2030-12-30
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well tafasitamab, lenalidomide and venetoclax work in treating
patients with mantle cell lymphoma that has come back (after a period of improvement)
(relapsed) or that has not responded to previous treatment (refractory). Tafasitamab is a
monoclonal antibody that may interfere with the ability of cancer cells to grow and spread.
Lenalidomide is in a class of medications called immunomodulatory agents. It works by helping
the immune system kill cancer cells. Venetoclax is in a class of medications called B-cell
lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a
protein needed for cancer cell survival. Giving tafasitamab, lenalidomide and venetoclax
together may kill cancer cells more efficiently in patients with relapsed or refractory
mantle cell lymphoma.